Quantcast

Latest Renal cell carcinoma Stories

2010-02-18 08:19:36

Researchers are able to predict and reverse resistance to a commonly used treatment Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer.  Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment. Kidney cancer is among the 10 most common cancers...

2010-02-04 15:24:37

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology. "Advanced renal cell carcinoma remains a challenging disease, but the outlook for patients has improved in the past year "“ including the addition of pazopanib, which targets multiple pathways within cancer cells," study author Dr. Cora N. Sternberg, chief of the medical...

2010-02-04 07:00:00

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that AVEO Pharmaceuticals' tivozanib, which is expected to launch in 2013 in the United States and Europe and in 2016 in Japan, will garner sales of up to $100 million by 2018 in the renal cell carcinoma drug market. The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma show that interviewed thought leaders...

2010-01-26 06:00:00

SAN DIEGO, Jan. 26 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States. Proleukin is a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic kidney cancer. Net sales for Proleukin were...

2010-01-12 17:50:11

Being obese could lead to a greater risk of developing the most common form of renal cell cancer, according to research in the January issue of the UK-based urology journal BJUI. US researchers found that obese patients with kidney tumors have 48 per cent higher odds of developing a clear-cell renal cell cancer (RCC) than patients with a body mass index (BMI) of less than 30. And the odds increase by four per cent for every extra BMI point. The team at the Memorial Sloan-Kettering Cancer...

cbce1b31846d6e7fe2319fba6542aa8d1
2010-01-07 08:20:10

Mutations in the genome regulation machinery identified in clear cell renal cell carcinoma In a new study, scientists have searched for mutations in the gene regions of more than 100 kidney cancer samples, the largest number of samples from a single tumor type to be sequenced to date. Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, with 102,000 deaths worldwide each year. It is noteworthy because its pathology "“ all the visible clues to its nature...

2009-11-09 06:00:00

Article published in December 2009 issue of the Journal of Urology QUEBEC CITY, Nov. 9 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer. The article outlines the...

2009-11-03 09:44:00

The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines. FORT WASHINGTON, Pa., Nov. 3 /PRNewswire-USNewswire/ -- Following the...

2009-10-19 19:17:00

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved VOTRIENT(TM) (pazopanib) to treat patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. Approximately 57,700 people in the U.S. will be diagnosed with kidney cancer this year, and 13,000 people will die from this disease. "RCC is the most common malignancy of the kidney and is highly resistant to chemotherapy,"...

2009-10-19 17:30:00

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related